# Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL

> **NCT05259813** · PHASE1 · WITHDRAWN · sponsor: **Shanghai Ming Ju Biotechnology Co., Ltd.**

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **GENETIC:** JWCAR029 (Relmacabtagene Autoleucel)

## Key facts

- **NCT ID:** NCT05259813
- **Lead sponsor:** Shanghai Ming Ju Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-02-28
- **Primary completion:** 2023-01-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to the COVID-19 pandemic，no subjects enrolled
- **Last updated:** 2023-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05259813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05259813, "Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05259813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*